Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder
暂无分享,去创建一个
[1] M. Holtze,et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.
[2] S. Erhardt,et al. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice , 2012, Journal of Neural Transmission.
[3] R. Schwarcz,et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. , 2011, Schizophrenia bulletin.
[4] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[5] M. Landén,et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. , 2011, Journal of psychiatry & neuroscience : JPN.
[6] M. Ingvar,et al. Manic episodes are associated with grey matter volume reduction — a voxel‐based morphometry brain analysis , 2010, Acta psychiatrica Scandinavica.
[7] S. Powell,et al. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. , 2010, The international journal of neuropsychopharmacology.
[8] E. Jönsson,et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. , 2010, Journal of psychiatry & neuroscience : JPN.
[9] R. Schwarcz,et al. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. , 2010, Schizophrenia bulletin.
[10] S. Rossell,et al. Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. , 2009, The international journal of neuropsychopharmacology.
[11] D. Bucci,et al. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning , 2009, Behavioural Brain Research.
[12] K N Roy Chengappa,et al. Identifying and treating cognitive impairment in bipolar disorder. , 2009, Bipolar disorders.
[13] K. Larsson,et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. , 2009, The international journal of neuropsychopharmacology.
[14] A. Carlsson,et al. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.
[15] M. Holtze,et al. Induction of the kynurenine pathway by neurotropic influenza a virus infection , 2008, Journal of neuroscience research.
[16] S. Erhardt,et al. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. , 2008, Life sciences.
[17] J. Meador-Woodruff,et al. Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder , 2008, Neuropsychopharmacology.
[18] S. Erhardt,et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis , 2007, Neuropharmacology.
[19] Gilles J Guillemin,et al. Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.
[20] D. Bucci,et al. Elevations of endogenous kynurenic acid produce spatial working memory deficits. , 2007, Schizophrenia bulletin.
[21] R. Panizzutti,et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia , 2007, Schizophrenia Research.
[22] W. Turski,et al. Enhancement of brain kynurenic acid production by anticonvulsants--novel mechanism of antiepileptic activity? , 2006, European journal of pharmacology.
[23] D. Bucci,et al. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding , 2006, Behavioural Brain Research.
[24] S. Erhardt,et al. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons , 2006, Journal of Neural Transmission.
[25] S. Erhardt,et al. Effects of COX‐1 and COX‐2 inhibitors on the firing of rat midbrain dopaminergic neurons—Possible involvement of endogenous kynurenic acid , 2006, Synapse.
[26] S. Weis,et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder , 2006, Brain Research.
[27] R. Schwarcz,et al. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain , 2006, Journal of Neural Transmission.
[28] K. Blennow,et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.
[29] M. Geyer,et al. Endogenous kynurenic acid disrupts prepulse inhibition , 2004, Biological Psychiatry.
[30] D. Kupfer,et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) , 2003, Biological Psychiatry.
[31] L. Clerkin,et al. Micromolar Brain Levels of Kynurenic Acid are Associated with a Disruption of Auditory Sensory Gating in the Rat , 2003, Neuropsychopharmacology.
[32] S. Erhardt,et al. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. , 2002, Acta physiologica Scandinavica.
[33] K. Blennow,et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.
[34] R. Schwarcz,et al. Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.
[35] R. Schwarcz,et al. The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.
[36] John E. Cooper,et al. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.
[37] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[38] J. Seibyl,et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.
[39] A. Malhotra,et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.
[40] R. Roth,et al. The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.
[41] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[42] C. Parsons,et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. , 1997, The Journal of pharmacology and experimental therapeutics.
[43] Anil K Malhotra,et al. Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.
[44] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Schwarcz,et al. Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: A light and electron microscopic study , 1992, The Journal of comparative neurology.
[47] M. Beal,et al. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. , 1990, Analytical biochemistry.
[48] G. Lynch,et al. A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.
[49] C. Grossman,et al. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.
[50] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[51] R. C. Young,et al. A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.
[52] D. Murphy,et al. Regular Induction of Hypomania by L-Dopa in “Bipolar” Manic-depressive Patients , 1971, Nature.
[53] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[54] E. Jönsson,et al. Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. , 2007, Journal of psychiatric research.
[55] N. King,et al. Molecules in focus: indoleamine 2,3-dioxygenase. , 2007, The international journal of biochemistry & cell biology.
[56] B. Kepplinger,et al. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. , 2005, Neuro-Signals.
[57] R. Schwarcz,et al. Kynurenate production by cultured human astrocytes , 2003, Journal of Neural Transmission.
[58] R. Schwarcz,et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[59] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[60] A. Ganong,et al. Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. , 1986, The Journal of pharmacology and experimental therapeutics.
[61] H. Wright,et al. Phencyclidine-induced psychosis. , 1980, Southern medical journal.